Spyre Therapeutics Inc
NASDAQ:SYRE

Watchlist Manager
Spyre Therapeutics Inc Logo
Spyre Therapeutics Inc
NASDAQ:SYRE
Watchlist
Price: 15.76 USD 1.68% Market Closed
Market Cap: 951.1m USD

Intrinsic Value

SYRE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one SYRE stock under the Base Case scenario is 9.99 USD. Compared to the current market price of 15.76 USD, Spyre Therapeutics Inc is Overvalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SYRE Intrinsic Value
9.99 USD
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare SYRE to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SYRE?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Spyre Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Spyre Therapeutics Inc

Current Assets 608.5m
Cash & Short-Term Investments 603.1m
Other Current Assets 5.4m
Non-Current Assets 10k
Other Non-Current Assets 10k
Efficiency

Free Cash Flow Analysis
Spyre Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Spyre Therapeutics Inc

Revenue
0 USD
Operating Expenses
-208.6m USD
Operating Income
-208.6m USD
Other Expenses
548k USD
Net Income
-208m USD
Fundamental Scores

SYRE Profitability Score
Profitability Due Diligence

Spyre Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score

Spyre Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

SYRE Solvency Score
Solvency Due Diligence

Spyre Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Spyre Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SYRE Price Targets Summary
Spyre Therapeutics Inc

Wall Street analysts forecast SYRE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SYRE is 55.42 USD with a low forecast of 21.21 USD and a high forecast of 74.55 USD.

Lowest
Price Target
21.21 USD
35% Upside
Average
Price Target
55.42 USD
252% Upside
Highest
Price Target
74.55 USD
373% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Spyre Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SYRE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SYRE Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SYRE stock?

The intrinsic value of one SYRE stock under the Base Case scenario is 9.99 USD.

Is SYRE stock undervalued or overvalued?

Compared to the current market price of 15.76 USD, Spyre Therapeutics Inc is Overvalued by 37%.

Back to Top